TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need.

TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplantation-related inflammatory disorders.  

Half-year financial results - Conference call and webcast

A conference call and webcast in English will be held on Wednesday, September 28 at 3:30pm CET. To participate: 

Following the live call, a replay will be available for 90 days. To listen to the replay, please dial: +33 (0)1 72 00 15 00 / 303497# 

2015 Registration Document (Document de Référence) - 24/05/2016   

Half-year financial results - Conference call presentation
Sept. 28, 2016

 DDR 2014             HY2016 firstslide EN

Arnaud Foussat, "Multiple ways to genetically alter T cells", MedNous, Vol 10, N° 7, July-August 2016, 6-7.

MedNous July-August 2016 issue - Arnaud Foussat commentary        




August 21-26, 2016
International Congress of Immunology 2016 (ICI 2016), Melbourne, Australia


September 21-22, 2016
Phacilitate Leaders Forum (including both Cell & Gene Therapy Europe and Immunotherapy Europe), Berlin, Germany


September 30 - October 2, 2016
International Society for Cellular Therapy (ISCT) North America 2016 Regional Meeting, Memphis, United States